Biocon Limited has informed the Exchange about Investor Presentation

Mgmt Guided Margin ImprovementInvestor Communications View source PDF

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+2.6%1-day move

₹382.30

prior close

₹379.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+4.4+3.6+3.7+2.7+2.6+5.6+8.9+9.4+12.6+12.4+11.7+6.7+4.0—

Up moveDown movePending

AI summary

Biocon reported Q4 FY26 revenue of ₹4,517 crore (up 10% YoY) and full year FY26 revenue of ₹16,927 crore (up 13% YoY). EBITDA for FY26 stood at ₹3,798 crore with 22% margin. Net profit before exceptional items jumped 323% YoY to ₹436 crore for FY26. The company completed integration of Biocon Biologics and major capacity build-out is largely behind them. Biosimilars segment drove growth with Q4 revenue up 12% YoY and 26% EBITDA margin. BMS partnership extended to 2035 in CRDMO business. Management flagged focus on operating leverage and margin improvement for FY27 as the company transitions from investment to execution phase.

Likely market impact

The filing signals improving profitability and operational efficiency with strong margin trajectory. The transition from investment to execution phase, combined with completed deleveraging and cost savings, suggests better bottom-line performance ahead for shareholders.